Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03445793 · ClinicalTrials.gov registry record
: TRANSITION: An Observational Study of Transition From Lumacaftor/Ivacaftor to Tezacaftor/Ivacaftor (Tez/Iva)
A clinical trial of Cystic Fibrosis (CF), sponsored by National Jewish Health.
- Completed
- Registry status
- 5
- Enrollment target
- 1
- Study location
NCT03445793: Completed study of Cystic Fibrosis (CF), sponsored by National Jewish Health.
NCT03445793 is a study of Cystic Fibrosis (CF) that has completed, run by National Jewish Health. The registered enrollment target is 5 participants, below the 141-participant average among 14 other Cystic Fibrosis (CF) trials with a reported enrollment target (96% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03445793, a study of Cystic Fibrosis (CF), has completed, sponsored by National Jewish Health.
- COMPLETED
- Registry status
- 5 participants
- Enrollment target
- 1
- Study location
Study Summary
This study is a single center study of clinical and laboratory outcomes in patients ≥ 12 who transition from use of Orkambi to tez/iva. Clinical and laboratory measurements will be measured at baseline, 1 month, 3 months, and 6 months after initiation of tez/iva. Change from baseline at 6 months pre-specified will be reported. The length of study participation will be approximately 6 months.
Primary Outcome
Sweat chloride is a measure of cystic fibrosis transmembrane conductance regulator function. The calculations represent the average change from baseline to the average change at 6 months.
Conditions Studied
Study Locations (1)
Colorado
- National Jewish Heatlh - Denver
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 5 participants |
| Start Date | 2018-03-01 |
| Est. Completion | 2019-11-01 |
What the finished NCT03445793 record still lists
NCT03445793 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 5 participants, a relatively small participant target, below the 141-participant average among 14 other Cystic Fibrosis (CF) trials with a reported enrollment target (96% lower).
The record links to 1 condition, with Cystic Fibrosis (CF) appearing as the primary indexed condition, and to 0 interventions.
NCT03445793 reports a single indexed study location in Colorado.
Frequently Asked Questions
What is clinical trial NCT03445793 about?
NCT03445793 is a clinical study titled ": TRANSITION: An Observational Study of Transition From Lumacaftor/Ivacaftor to Tezacaftor/Ivacaftor (Tez/Iva)". This study is a single center study of clinical and laboratory outcomes in patients ≥ 12 who transition from use of Orkambi to tez/iva. Clinical and laboratory measurements will be measured at baseline, 1 month, 3 months, and 6 months after initiation of tez/iva. Change from baseline at 6 months pre...
What is the current status of trial NCT03445793?
This trial is currently completed. The enrollment target is 5 participants. The study started on 2018-03-01. Estimated completion is 2019-11-01.
What conditions does trial NCT03445793 study?
This clinical trial studies the following conditions: Cystic Fibrosis (CF).
Who is sponsoring clinical trial NCT03445793?
This trial is sponsored by National Jewish Health, which has 83 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03445793 being conducted?
This trial has 1 study location across Colorado. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Cystic Fibrosis (CF)
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03445793's enrollment target sits among peer trials
5 15th of 14 the lowest of 14 other Cystic Fibrosis (CF) trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Cystic Fibrosis (CF) trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Lung Disease and Its Affect on the Work of White Blood Cells in the Lungs
RECRUITING
-
Sinonasal Therapies and Histologic Correlations of Patients With Cystic Fibrosis in the Era of Highly Effective Modulator Therapy
RECRUITING · Phase 3
-
Personalized Mobile Health Platform to Promote Physical Activity in Adolescents and Young Adults With Cystic Fibrosis
RECRUITING · NA
-
Studying the Presence of CFRD Complications With Thoughtful Recruitment (SPeCTRuM)
RECRUITING
-
Study With Phage for CF Subjects With Pseudomonas Lung Infection
RECRUITING · Phase 2
-
Kidney Function in People With Cystic Fibrosis in the Era of HEMT
RECRUITING
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI